Starting Dose for Vyvanse in a 12-Year-Old
The appropriate starting dose of lisdexamfetamine (Vyvanse) for a 12-year-old with ADHD is 30 mg once daily in the morning. 1
FDA-Approved Dosing
According to the FDA drug label, Vyvanse is available in doses of 10,20,30,40,50,60, and 70 mg, with the standard starting dose being 30 mg once daily 1. The medication can be titrated in increments of 10 or 20 mg at approximately weekly intervals up to a maximum of 70 mg daily, based on clinical response and tolerability.
Key Dosing Considerations
Age-Appropriate Dosing
- A 12-year-old falls within the pediatric age range (6-12 years) where Vyvanse has been extensively studied and FDA-approved
- Pharmacokinetic studies demonstrate that weight/dose normalized exposure (AUC and Cmax) is equivalent between children aged 6-12 years and adults at doses of 30-70 mg 1
- The medication exhibits linear pharmacokinetics in this age range, making dose adjustments predictable
Duration of Effect
- Vyvanse provides approximately 12-13 hours of symptom control with once-daily dosing 2, 3
- Peak plasma concentrations of the active metabolite (dextroamphetamine) occur approximately 3.5 hours post-dose 1
- This extended duration makes it suitable for full-day coverage including school and homework time
Titration Strategy
After starting at 30 mg:
- Assess response after 1 week of treatment
- If inadequate response and medication is well-tolerated, increase by 10-20 mg increments
- Common effective doses range from 30-70 mg daily 4, 5
- Clinical trials show efficacy across all doses (30,50,70 mg), with dose-dependent improvements in ADHD symptoms 4
Administration Guidelines
- Give once daily in the morning (can be taken with or without food) 1
- Food delays time to peak concentration by approximately 1 hour but does not affect overall absorption
- Capsules can be swallowed whole or opened and mixed with water (entire contents should be consumed immediately)
- Chewable tablets are also available as an alternative formulation
Safety Monitoring
Before and during treatment, monitor:
- Cardiovascular parameters: Pulse and blood pressure at baseline and periodically during treatment
- Growth parameters: Height and weight, as decreased appetite (39% incidence) and weight loss are common 4
- Psychiatric symptoms: Assess for substance use history in adolescents before initiating treatment 6
- Sleep disturbances: Insomnia occurs in approximately 19% of patients 4
Common Adverse Effects
The most frequent side effects in pediatric patients include 4, 5:
- Decreased appetite (39-47%)
- Insomnia (19-27%)
- Upper abdominal pain (12-16%)
- Headache (12-17%)
- Irritability (10-16%)
Most adverse effects are mild to moderate and occur predominantly in the first week of treatment 4.
Clinical Pitfalls to Avoid
Don't start too low in older children: While 10-20 mg doses exist, they are typically reserved for younger children (ages 6-8) or those with significant sensitivity concerns. Starting at 30 mg in a 12-year-old is appropriate and supported by clinical trial data 4
Don't rush titration: Allow at least one week at each dose to assess full therapeutic effect before increasing
Don't forget substance use screening: Guidelines specifically emphasize assessing adolescents for substance use symptoms before initiating stimulant treatment 6
Don't ignore cardiovascular screening: Obtain baseline vital signs and assess for cardiac risk factors or family history of sudden cardiac death
Evidence Quality
The 30 mg starting dose recommendation is based on FDA drug labeling 1 and supported by multiple Phase III randomized controlled trials demonstrating efficacy and safety at this dose in children aged 6-12 years 4, 2. Recent guidelines from the American Academy of Pediatrics (2019) support stimulants as first-line pharmacologic treatment for school-aged children with ADHD 6, and a 2022 pharmacotherapy review confirms lisdexamfetamine as an appropriate first-line option (though approval status varies by country) 7.